Jason Coloma, Maze Therapeutics CEO
January 7, 2025 05:36 PM EST
Financing
Startups

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Kyle LaHucik

Senior Reporter

Maze Ther­a­peu­tics has sub­mit­ted its pitch for an ini­tial pub­lic of­fer­ing af­ter dis­clos­ing a $115 mil­lion Se­ries D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Pfiz­er, GSK add risk of Guil­lain-Bar­ré to RSV vac­cine la­bels at FDA's re­quest

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

A service from the Financial Times